Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study

BACKGROUND/AIMS: Only moderate to severe Crohn's Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Jap...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Chang, Chen-Wang, Wei, Shu-Chen, Chou, Jen-Wei, Hsu, Tzu-Chi, Chuang, Chiao-Hsiung, Lin, Ching-Pin, Hsu, Wen-Hung, Yen, Hsu-Heng, Lin, Jen-Kou, Fang, Yi-Jen, Wang, Horng-Yuan, Lin, Hung-Hsin, Wu, Deng Cheng, Ni, Yen Hsuan, Wang, Cheng-Yi, Wong, Jau-Min
Format: Artigo
Sprache:Inglês
Veröffentlicht: Korean Association for the Study of Intestinal Diseases 2014
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4214955/
https://ncbi.nlm.nih.gov/pubmed/25374494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2014.12.4.287
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge